Arnaud Wiedemann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Arnaud Wiedemann has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
Emeline Renard
CHRU- Nancy, Department of Pediatrics, 54500 Vandœuvre-Les-Nancy, France
3 shared publicationsAymeric Barbarino
Clinical Decision Support System Artificial Intelligence Health Cluster in Acute Child Care, CHU Sainte-Justine, Montréal, Canada
2 shared publicationsElise Jeannesson
Pediatric Department, Reference Center of Inborn Errors of Metabolism (ORPHA67872), University Regional Hospital Center of Nancy, INSERM UMRS 1256 NGERE—Nutrition, Genetics, and Environmental Risk Exposure, Nancy, France
2 shared publicationsFlorent Girard
2 shared publicationsFrançois Feillet
Pediatric Department, Reference Center of Inborn Errors of Metabolism (ORPHA67872), University Regional Hospital Center of Nancy, INSERM UMRS 1256 NGERE—Nutrition, Genetics, and Environmental Risk Exposure, Nancy, France
2 shared publications- François Feillet
Pediatric Unit, Reference Center for Inborn Errors of Metabolism, University Hospital of Nancy, INSERM UMR_S1256 NGERE, University of Lorraine, Nancy, France
2 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Restoring brain functions in the Mo-blo mouse model of Menkes disease with copper nanoclusters
Menkes disease, caused by ATP7A mutations, leads to severe copper deficiency and fatal neurodegeneration. Current copper-histidine therapy fails to restore brain function. Copper nanoclusters (CuNCs) were designed for their ultrasmall size to cross physiological barriers and deliver copper directly to the whole organism, including the brain. In Mo-blo mice (ATP7A deficient), daily subcutaneous CuNCs markedly improved survival, normalized cuproprotein activities, and restored cognitive and motor functions. Unlike other treatments, CuNCs effectively penetrate the blood-brain barrier, deliver copper to cuproproteins, offering unprecedented neurological rescue. This breakthrough could transform Menkes disease treatment, providing a first-ever therapy for brain copper deficiency. Further clinical development may unlock lifesaving solutions for this rare, fatal disorder.
- 2 October 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (40)
Open AccessRestoring brain functions in the Mo-blo mouse model of Menkes disease with copper nanoclusters
Menkes disease, caused by ATP7A mutations, leads to severe copper deficiency and fatal neurodegeneration. Current copper-histidine therapy fails to restore brain function. Copper nanoclusters (CuNCs) were designed for their ultrasmall size to cross physiological barriers and deliver copper directly to the whole organism, including the brain. In Mo-blo mice (ATP7A deficient), daily subcutaneous CuNCs markedly improved survival, normalized cuproprotein activities, and restored cognitive and motor functions. Unlike other treatments, CuNCs effectively penetrate the blood-brain barrier, deliver copper to cuproproteins, offering unprecedented neurological rescue. This breakthrough could transform Menkes disease treatment, providing a first-ever therapy for brain copper deficiency. Further clinical development may unlock lifesaving solutions for this rare, fatal disorder.
- Open Access
- 3 August 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (8) , e1413
Amino Acid Deficiency Secondary to Continuous Venovenous Hemofiltration in Acute Decompensation of Organic Acidemias: An Anabolic Dead End?
OBJECTIVE: To evaluate the impact of continuous renal replacement therapy (CRRT) on plasma amino acid (AA) concentrations in patients with acute metabolic decompensation of organic acidemias (OAs), and to explore whether AA supplementation during CRRT may mitigate AA depletion. DESIGN: Multicenter retrospective observational study. SETTING: PICUs managing acute metabolic decompensations of OAs. PATIENTS OR SUBJECTS: Patients with confirmed OAs who underwent CRRT for severe acute metabolic decompensation. INTERVENTIONS: CRRT was initiated according to current guidelines in cases of severe decompensation. Standard metabolic management included high caloric intake through carbohydrates and lipids with temporary protein withdrawal (24–48 hr). In one patient, AA supplementation (2 g/kg) during CRRT combined with thiamin and citrate (anaplerotic therapy) was administered. MEASUREMENTS AND MAIN RESULTS: Plasma AA concentrations were measured before and after CRRT in nine patients with a median age of 21 days (interquartile range [IQR], 3–570 d). Quantitative variables are expressed as medians (IQR, 25th–75th). Before CRRT, 31% (95% CI, 24–39) of plasma AAs were below the normal range compared with 69% (95% CI, 59–77) after CRRT ( p < 0.0001). A significant increase in lactatemia was observed following CRRT, without evidence of organ failure: median 2.2 mmol/L (IQR, 1.3–2.3) before CRRT vs. 5.3 mmol/L (IQR, 3.2–7.1) after CRRT; Hodges-Lehmann median difference +3.2 (95% CI, 0.8–5.6; p = 0.0065). In the patient receiving AA supplementation with anaplerotic therapy, plasma AA status improved markedly, with 65% of AAs below normal before CRRT vs. 15% after CRRT. CONCLUSIONS: In acute decompensated OAs, CRRT performed without protein supplementation, as currently recommended, significantly reduces total plasma AA concentrations and may impair restoration of anabolism. AA infusion during CRRT could help preserve or restore protein anabolism. Prospective studies are needed to assess the safety and efficacy of AA supplementation during CRRT, with or without anaplerotic therapy, in this setting.
- 3 August 2026
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 8 (8) , e1413
Open AccessAmino Acid Deficiency Secondary to Continuous Venovenous Hemofiltration in Acute Decompensation of Organic Acidemias: An Anabolic Dead End?
OBJECTIVE: To evaluate the impact of continuous renal replacement therapy (CRRT) on plasma amino acid (AA) concentrations in patients with acute metabolic decompensation of organic acidemias (OAs), and to explore whether AA supplementation during CRRT may mitigate AA depletion. DESIGN: Multicenter retrospective observational study. SETTING: PICUs managing acute metabolic decompensations of OAs. PATIENTS OR SUBJECTS: Patients with confirmed OAs who underwent CRRT for severe acute metabolic decompensation. INTERVENTIONS: CRRT was initiated according to current guidelines in cases of severe decompensation. Standard metabolic management included high caloric intake through carbohydrates and lipids with temporary protein withdrawal (24–48 hr). In one patient, AA supplementation (2 g/kg) during CRRT combined with thiamin and citrate (anaplerotic therapy) was administered. MEASUREMENTS AND MAIN RESULTS: Plasma AA concentrations were measured before and after CRRT in nine patients with a median age of 21 days (interquartile range [IQR], 3–570 d). Quantitative variables are expressed as medians (IQR, 25th–75th). Before CRRT, 31% (95% CI, 24–39) of plasma AAs were below the normal range compared with 69% (95% CI, 59–77) after CRRT ( p < 0.0001). A significant increase in lactatemia was observed following CRRT, without evidence of organ failure: median 2.2 mmol/L (IQR, 1.3–2.3) before CRRT vs. 5.3 mmol/L (IQR, 3.2–7.1) after CRRT; Hodges-Lehmann median difference +3.2 (95% CI, 0.8–5.6; p = 0.0065). In the patient receiving AA supplementation with anaplerotic therapy, plasma AA status improved markedly, with 65% of AAs below normal before CRRT vs. 15% after CRRT. CONCLUSIONS: In acute decompensated OAs, CRRT performed without protein supplementation, as currently recommended, significantly reduces total plasma AA concentrations and may impair restoration of anabolism. AA infusion during CRRT could help preserve or restore protein anabolism. Prospective studies are needed to assess the safety and efficacy of AA supplementation during CRRT, with or without anaplerotic therapy, in this setting.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude comparative des aspects cliniques et physiopathologiques des erreurs innées du métabolisme de la vitamine B12 en fonction de l’âge
Le métabolisme de la vitamine B12 est un processus complexe aboutissant à la synthèse des deux formes actives : l’adénosylcobalamine, cofacteur de la méthylmalonyl-CoA mutase, et la méthylcobalamine, cofacteur de la méthionine synthase, indispensable aux réactions de méthylation de l’organisme. Les erreurs innées du métabolisme de la vitamine B12 sont des pathologies rares consécutives à un déficit d’une protéine ou d’une enzyme sur le transport, l’internalisation ou l’utilisation intracellulaire de la vitamine B12. Les manifestations cliniques et métaboliques présentées par les patients offrent une grande diversité de présentation selon l’âge d’apparition des premiers symptômes et le gène muté. Nous avons réalisé une méta-analyse rassemblant l’ensemble des descriptions de 824 patients ayant un déficit génétiquement documenté du métabolisme de la vitamine B12. Nous avons pu souligner l’apparition de manifestations neurologiques (trouble de la marche, atrophie cérébrale, neuropathie périphérique) avec l’âge, tout comme celle de manifestations cardiovasculaires (hypertension artérielle, thrombose). Ces profils neurologiques et cardio-vasculaires soulignent l’importance d’évoquer une erreur innée du métabolisme de la vitamine B12, et la recherche génétique d’un tel déficit en cas de profil évocateur. La deuxième partie de ce travail a objectivé le rendement diagnostique d’un exome clinique comme test génétique de premier niveau au sein d’une population pédiatrique de 128 enfants consécutifs. 60% des CES étaient positifs en cas d’anomalie biochimique évocatrice, pour un délai médian de 5 mois, offrant un test diagnostique performant pour l’identification d’une IEM-B12. La troisième partie de ce travail a mis en évidence dans des fibroblastes de patient une variation d’expression aux niveaux métabolomique, transcriptomique, protéomique et de modification post-traductionnelle (tel que l’ajout de propionaldéhyde) d’enzymes impliqués dans le métabolisme, notamment mitochondriale, associés à d’autres pathologies dont les manifestations cliniques permettent d’expliquer la variabilité clinique observer dans les IEM-B12.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Etude comparative des aspects cliniques et physiopathologiques des erreurs innées du métabolisme de la vitamine B12 en fonction de l’âge
Le métabolisme de la vitamine B12 est un processus complexe aboutissant à la synthèse des deux formes actives : l’adénosylcobalamine, cofacteur de la méthylmalonyl-CoA mutase, et la méthylcobalamine, cofacteur de la méthionine synthase, indispensable aux réactions de méthylation de l’organisme. Les erreurs innées du métabolisme de la vitamine B12 sont des pathologies rares consécutives à un déficit d’une protéine ou d’une enzyme sur le transport, l’internalisation ou l’utilisation intracellulaire de la vitamine B12. Les manifestations cliniques et métaboliques présentées par les patients offrent une grande diversité de présentation selon l’âge d’apparition des premiers symptômes et le gène muté. Nous avons réalisé une méta-analyse rassemblant l’ensemble des descriptions de 824 patients ayant un déficit génétiquement documenté du métabolisme de la vitamine B12. Nous avons pu souligner l’apparition de manifestations neurologiques (trouble de la marche, atrophie cérébrale, neuropathie périphérique) avec l’âge, tout comme celle de manifestations cardiovasculaires (hypertension artérielle, thrombose). Ces profils neurologiques et cardio-vasculaires soulignent l’importance d’évoquer une erreur innée du métabolisme de la vitamine B12, et la recherche génétique d’un tel déficit en cas de profil évocateur. La deuxième partie de ce travail a objectivé le rendement diagnostique d’un exome clinique comme test génétique de premier niveau au sein d’une population pédiatrique de 128 enfants consécutifs. 60% des CES étaient positifs en cas d’anomalie biochimique évocatrice, pour un délai médian de 5 mois, offrant un test diagnostique performant pour l’identification d’une IEM-B12. La troisième partie de ce travail a mis en évidence dans des fibroblastes de patient une variation d’expression aux niveaux métabolomique, transcriptomique, protéomique et de modification post-traductionnelle (tel que l’ajout de propionaldéhyde) d’enzymes impliqués dans le métabolisme, notamment mitochondriale, associés à d’autres pathologies dont les manifestations cliniques permettent d’expliquer la variabilité clinique observer dans les IEM-B12.
- 20 March 2026
- Published by S. Karger AG in Blood Purification
- Vol. 55 (5) , 296-309
Circuit Survival in Children with Hemolytic Uremic Syndrome Requiring Continuous Renal Replacement Therapy
Introduction: Hemolytic uremic syndrome (HUS) is a significant cause of acute kidney injury (AKI) in children that is caused by Shiga toxin-producing Escherichia coli. Continuous renal replacement therapy (CRRT) is frequently used for managing AKI in critically ill pediatric patients. The filter lifespan is a crucial factor affecting its effectiveness and cost. This study aimed to investigate the impact of HUS on the lifespan of CRRT filters compared with that of other etiologies. Materials and Methods: This retrospective longitudinal study was conducted in a pediatric intensive care unit in Nancy, France, from January 2013 to December 2023. The study included 54 children requiring CRRT, with 388 filters (202 in the HUS group and 186 in the other etiologies group). Data on filter lifespan and various parameters were collected and analyzed according to disease (HUS group or other etiologies) and the type of anticoagulation used. Results: The median lifespan of the filters in the HUS group was shorter than that in the other etiologies group (13.3 h vs. 17.6 h, p = 0.05). This study revealed no significant difference in filter lifespan between regional citrate anticoagulation and systemic unfractionated heparin in pediatric patients with typical HUS (p = 1.00). Conclusion: The prothrombotic nature of HUS, characterized by platelet activation, may contribute to the observed decrease in lifespan. The mechanism of coagulation activation in HUS and its interaction with hemofiltration, including the effects of platelets and blood product transfusions, remain to be explored. The lifespan of the filters is shorter in patients with HUS than in those with other etiologies, regardless of the type of anticoagulation used.
- 20 March 2026
- Published by S. Karger AG in Blood Purification
- Vol. 55 (5) , 296-309
Circuit Survival in Children with Hemolytic Uremic Syndrome Requiring Continuous Renal Replacement Therapy
Introduction: Hemolytic uremic syndrome (HUS) is a significant cause of acute kidney injury (AKI) in children that is caused by Shiga toxin-producing Escherichia coli. Continuous renal replacement therapy (CRRT) is frequently used for managing AKI in critically ill pediatric patients. The filter lifespan is a crucial factor affecting its effectiveness and cost. This study aimed to investigate the impact of HUS on the lifespan of CRRT filters compared with that of other etiologies. Materials and Methods: This retrospective longitudinal study was conducted in a pediatric intensive care unit in Nancy, France, from January 2013 to December 2023. The study included 54 children requiring CRRT, with 388 filters (202 in the HUS group and 186 in the other etiologies group). Data on filter lifespan and various parameters were collected and analyzed according to disease (HUS group or other etiologies) and the type of anticoagulation used. Results: The median lifespan of the filters in the HUS group was shorter than that in the other etiologies group (13.3 h vs. 17.6 h, p = 0.05). This study revealed no significant difference in filter lifespan between regional citrate anticoagulation and systemic unfractionated heparin in pediatric patients with typical HUS (p = 1.00). Conclusion: The prothrombotic nature of HUS, characterized by platelet activation, may contribute to the observed decrease in lifespan. The mechanism of coagulation activation in HUS and its interaction with hemofiltration, including the effects of platelets and blood product transfusions, remain to be explored. The lifespan of the filters is shorter in patients with HUS than in those with other etiologies, regardless of the type of anticoagulation used.
- 27 February 2026
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 17 (4) , 558-559
Response to Reader Comment on “Risk Factors and Causes of Readmission to the Pediatric Intensive Care Unit After Cardiac Surgery”
- 27 February 2026
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 17 (4) , 558-559
Response to Reader Comment on “Risk Factors and Causes of Readmission to the Pediatric Intensive Care Unit After Cardiac Surgery”
- 17 November 2025
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 17 (3) , 362-368
Risk Factors and Causes of Readmission to the Pediatric Intensive Care Unit After Cardiac Surgery
Introduction: Unplanned readmissions to the pediatric intensive care unit (PICU) following cardiac surgery remain poorly understood. Such readmissions are associated with increased morbidity and present significant challenges to healthcare. This study aimed to identify characteristics associated with unplanned PICU readmission during the same hospitalization following cardiac surgery. Method: We conducted a retrospective analysis using prospectively collected data from a tertiary care children's hospital from January 2015 to January 2021. All pediatric patients who underwent cardiac surgery and were transferred alive from the PICU were included. Each patient readmitted to the PICU was matched to two controls based on age and PELOD score at the time of initial PICU admission postsurgery to identify factors associated with readmission among 72 variables. Results: Of the 956 patients discharged alive from the PICU after cardiac surgery, 23 (2.4%) required unplanned readmission. Over half (12/23, 52.2%) of these readmissions occurred within 48 h of PICU discharge. Univariate analysis identified preoperative arrhythmias ( P = .037) and postoperative single-ventricle physiology ( P = .024) as potential risk factors for readmission. Male sex appeared to be a protective factor against unplanned PICU readmission ( P = .026). Although preoperative vasopressor requirement, postoperative altered ventricular function and known pleural effusion at PICU discharge were not significantly associated with PICU readmission, these factors showed a trend toward significance. After multivariate analysis, postoperative single-ventricle physiology remained the sole independent risk factor associated with unplanned PICU readmission with an odds ratio of 8.6 (95% confidence interval, 1.9-46.5). Conclusion: While unscheduled PICU readmissions following cardiac surgery are rare, postoperative single-ventricle physiology emerged as an independent risk factor.
- 17 November 2025
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 17 (3) , 362-368
Risk Factors and Causes of Readmission to the Pediatric Intensive Care Unit After Cardiac Surgery
Introduction: Unplanned readmissions to the pediatric intensive care unit (PICU) following cardiac surgery remain poorly understood. Such readmissions are associated with increased morbidity and present significant challenges to healthcare. This study aimed to identify characteristics associated with unplanned PICU readmission during the same hospitalization following cardiac surgery. Method: We conducted a retrospective analysis using prospectively collected data from a tertiary care children's hospital from January 2015 to January 2021. All pediatric patients who underwent cardiac surgery and were transferred alive from the PICU were included. Each patient readmitted to the PICU was matched to two controls based on age and PELOD score at the time of initial PICU admission postsurgery to identify factors associated with readmission among 72 variables. Results: Of the 956 patients discharged alive from the PICU after cardiac surgery, 23 (2.4%) required unplanned readmission. Over half (12/23, 52.2%) of these readmissions occurred within 48 h of PICU discharge. Univariate analysis identified preoperative arrhythmias ( P = .037) and postoperative single-ventricle physiology ( P = .024) as potential risk factors for readmission. Male sex appeared to be a protective factor against unplanned PICU readmission ( P = .026). Although preoperative vasopressor requirement, postoperative altered ventricular function and known pleural effusion at PICU discharge were not significantly associated with PICU readmission, these factors showed a trend toward significance. After multivariate analysis, postoperative single-ventricle physiology remained the sole independent risk factor associated with unplanned PICU readmission with an odds ratio of 8.6 (95% confidence interval, 1.9-46.5). Conclusion: While unscheduled PICU readmissions following cardiac surgery are rare, postoperative single-ventricle physiology emerged as an independent risk factor.
- 21 November 2023
- Published by Elsevier in Archives de Pédiatrie
- Vol. 31 (1) , 20-25
Identification of factors associated with the management of childhood obesity: Results from a French pediatric cohort study
- 21 November 2023
- Published by Elsevier in Archives de Pédiatrie
- Vol. 31 (1) , 20-25
Identification of factors associated with the management of childhood obesity: Results from a French pediatric cohort study
- 23 June 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (9) , 1-9
Procalcitonin is associated with sudden unexpected death in infancy due to infection
Infection is an important cause of death during infancy worldwide and is a frequent etiology of sudden unexpected death in infancy (SUDI). Procalcitonin (PCT) is a useful marker to diagnose infection in patients, and several studies report the stability of PCT after death. The added value of a biological marker, such as the PCT level in the blood, remains controversial in investigating SUDI. The aim of this study was to determine if PCT can help clinicians determine whether infection caused SUDI. We conducted a retrospective, multicenter study with the French SUDI registry (Observatoire National des Morts Inattendues du Nourrisson; OMIN). We collected data from this registry on children who died between May 2015 and June 2021. The levels of PCT in the blood of 540 SUDI patients were measured. We compared PCT and other biological tests performed in terms of infection status, autopsy results, and cause of death using clinical and biological data compiled by pediatricians at the SUDI referral center. PCT levels were significantly higher in the children who died from infection than in those who did not (0.12 µg/L vs. 0.08 µg/L, p < 0.001). A PCT blood level exceeding 0.2 µg/L was more frequently observed when infection was present than in the absence of infection (44.3% vs. 15.4%, p < 0.001). The same data were obtained with a 0.5 µg/L cut-off (36.1% with infection vs. 9.2% without, p < 0.001). Conclusions: PCT is a sensitive biomarker for detecting infections postmortem; thus, additional samples may be necessary during autopsy. What is known: • PCT is a stable marker postmortem and increases earlier than CRP, i.e., 2–4 h after the beginning of an infection vs. 6 h. • PCT can be measured up to 140 h after death. What is new: • PCT is a sensitive marker for detecting infection in SUDI patients postmortem. • This test can reveal an infection from non-standardized samples obtained during autopsy if such an infection was not determined before death.
- 23 June 2023
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 182 (9) , 1-9
Procalcitonin is associated with sudden unexpected death in infancy due to infection
Infection is an important cause of death during infancy worldwide and is a frequent etiology of sudden unexpected death in infancy (SUDI). Procalcitonin (PCT) is a useful marker to diagnose infection in patients, and several studies report the stability of PCT after death. The added value of a biological marker, such as the PCT level in the blood, remains controversial in investigating SUDI. The aim of this study was to determine if PCT can help clinicians determine whether infection caused SUDI. We conducted a retrospective, multicenter study with the French SUDI registry (Observatoire National des Morts Inattendues du Nourrisson; OMIN). We collected data from this registry on children who died between May 2015 and June 2021. The levels of PCT in the blood of 540 SUDI patients were measured. We compared PCT and other biological tests performed in terms of infection status, autopsy results, and cause of death using clinical and biological data compiled by pediatricians at the SUDI referral center. PCT levels were significantly higher in the children who died from infection than in those who did not (0.12 µg/L vs. 0.08 µg/L, p < 0.001). A PCT blood level exceeding 0.2 µg/L was more frequently observed when infection was present than in the absence of infection (44.3% vs. 15.4%, p < 0.001). The same data were obtained with a 0.5 µg/L cut-off (36.1% with infection vs. 9.2% without, p < 0.001). Conclusions: PCT is a sensitive biomarker for detecting infections postmortem; thus, additional samples may be necessary during autopsy. What is known: • PCT is a stable marker postmortem and increases earlier than CRP, i.e., 2–4 h after the beginning of an infection vs. 6 h. • PCT can be measured up to 140 h after death. What is new: • PCT is a sensitive marker for detecting infection in SUDI patients postmortem. • This test can reveal an infection from non-standardized samples obtained during autopsy if such an infection was not determined before death.
- Open Access
- 16 June 2021
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 30 (Hors-série) , 53-68
Le SARS-CoV-2 en réanimation pédiatrique
In a lesser extent than adults Intensive Care Units (ICUs), Pediatric ICUs (PICUs) had to deal with the SARS-CoV-2 pandemic. Pediatric intensivists managed serious pediatric forms of primary infections and then in a second stage, post-infectious systemic inflammatory attacks. Some of them helped with the management of adults with a severe form of SARS-CoV-2. Therefore, they had to adapt in record time. In this review, we report (i) the literature data on these two severe pediatric forms, the primary infection and the systemic inflammatory manifestations associated with SARS-CoV-2; (ii) the experience of PICUs in the management of critically ill adults with SARS-CoV-2 infection and (iii) and the impact of the pandemic on the place of families of children in critical situation in PICUs.
- 16 June 2021
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 30 (Hors-série) , 53-68
Open AccessLe SARS-CoV-2 en réanimation pédiatrique
In a lesser extent than adults Intensive Care Units (ICUs), Pediatric ICUs (PICUs) had to deal with the SARS-CoV-2 pandemic. Pediatric intensivists managed serious pediatric forms of primary infections and then in a second stage, post-infectious systemic inflammatory attacks. Some of them helped with the management of adults with a severe form of SARS-CoV-2. Therefore, they had to adapt in record time. In this review, we report (i) the literature data on these two severe pediatric forms, the primary infection and the systemic inflammatory manifestations associated with SARS-CoV-2; (ii) the experience of PICUs in the management of critically ill adults with SARS-CoV-2 infection and (iii) and the impact of the pandemic on the place of families of children in critical situation in PICUs.
- 12 April 2021
- Published by Mathematical Modelling and Numerical Simulation with Applications in Journal of Pediatric Neurology
- Vol. 20 (01) , 071-074
Vasodilator-Stimulated Phosphoprotein to Monitor Clopidogrel Posology in a 7-Year-Old Child Stented for a Post-Traumatic Intracranial Internal Carotid Artery Aneurysm
Many pediatric medical protocols or drug posology like biantiplatelet therapy are extrapolated from adult care. This association could be indicated in specific pediatric situations such as ischemic stroke, some cardiac conditions, or to control post stent thrombosis/stenosis. If acetylsalicylic acid is commonly used, few data are available about optimal management of clopidogrel in children. We describe the case of a 7-year-old girl admitted to pediatric intensive care unit who undergoes a transitory hemiparesis after a bicycle accident. Brain magnetic resonance imaging reveals a subarachnoid hemorrhage and a wide right Sylvian arachnoid cyst. Hemorrhage predominated at the level of the optochiasmatic cistern, close to the right internal carotid artery. At the same level, angiography revealed a small aneurysm of the internal carotid artery supposed to be a postfalse traumatic aneurysm. The deployment treated this aneurysm of a flow diverter. The treatment was performed under continuous systemic heparin therapy associated with intravenous acetylsalicylic acid, and Clopidogrel was administered immediately after the procedure. An oral bi antiplatelet treatment was initiated the day 2 with acetylsalicylic acid and clopidogrel (1 mg/kg/day). To monitor clopidogrel posology, a vasodilator-stimulated phosphoprotein [VASP]) was performed. The final VASP assay result was 20% for a clopidogrel posology at 0.5 mg/kg/day. Blood pressure and neurological examination were normal during all the hospitalization. VASP assay can be used in children to define the optimal posology of clopidogrel. Further studies are required to determine an optimal initial posology.
- 12 April 2021
- Published by Mathematical Modelling and Numerical Simulation with Applications in Journal of Pediatric Neurology
- Vol. 20 (01) , 071-074
Vasodilator-Stimulated Phosphoprotein to Monitor Clopidogrel Posology in a 7-Year-Old Child Stented for a Post-Traumatic Intracranial Internal Carotid Artery Aneurysm
Many pediatric medical protocols or drug posology like biantiplatelet therapy are extrapolated from adult care. This association could be indicated in specific pediatric situations such as ischemic stroke, some cardiac conditions, or to control post stent thrombosis/stenosis. If acetylsalicylic acid is commonly used, few data are available about optimal management of clopidogrel in children. We describe the case of a 7-year-old girl admitted to pediatric intensive care unit who undergoes a transitory hemiparesis after a bicycle accident. Brain magnetic resonance imaging reveals a subarachnoid hemorrhage and a wide right Sylvian arachnoid cyst. Hemorrhage predominated at the level of the optochiasmatic cistern, close to the right internal carotid artery. At the same level, angiography revealed a small aneurysm of the internal carotid artery supposed to be a postfalse traumatic aneurysm. The deployment treated this aneurysm of a flow diverter. The treatment was performed under continuous systemic heparin therapy associated with intravenous acetylsalicylic acid, and Clopidogrel was administered immediately after the procedure. An oral bi antiplatelet treatment was initiated the day 2 with acetylsalicylic acid and clopidogrel (1 mg/kg/day). To monitor clopidogrel posology, a vasodilator-stimulated phosphoprotein [VASP]) was performed. The final VASP assay result was 20% for a clopidogrel posology at 0.5 mg/kg/day. Blood pressure and neurological examination were normal during all the hospitalization. VASP assay can be used in children to define the optimal posology of clopidogrel. Further studies are required to determine an optimal initial posology.